大蒜素胶囊对癌症化疗患者细胞免疫功能的影响

中国综合临床 Pub Date : 2019-07-01 DOI:10.3760/CMA.J.ISSN.1008-6315.2019.04.010

Qi Zhou, Haiping Zhang

{"title":"大蒜素胶囊对癌症化疗患者细胞免疫功能的影响","authors":"Qi Zhou, Haiping Zhang","doi":"10.3760/CMA.J.ISSN.1008-6315.2019.04.010","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the effects of garlicin capsule on immune function in patients with breast cancer undergoing chemotherapy. \n \n \nMethods \nForm April 2018 to October 2018, 62 patients with breast cancer were treated by operation in Tangshan People′s Hospital and pathologically diagnosed as breast cancer.Random number table method was used to divide the patients into treatment group and control group, with 31 cases in each group.The treatment group was given garlicin capsule combined with EC regimen( the first day(epirubicin hydrochloride injection 90 mg/m2 + cyclophosphamide 90 mg/m2) , 21 days for one cycle, four consecutive cycles), while the control group was given EC regimen alone for 4 courses.The occurrence of adverse reactions was recorded.T lymphocyte subsets were detected before and after treatment to evaluate the immune function of the body. \n \n \nResults \nThere was no significant difference in the number of adverse reactions between the two groups after treatment (Seventy in the treatment group and 69 in the control group) (P>0.05). The levels of CD3+ , CD4+ , CD8+ and CD4+ /CD8+ were (53.76±4.29)%, (40.19±3.71)%, (28.61±2.75)% and (1.41±0.16) in the treatment group before chemotherapy, respectively.While after chemotherapy were (52.41±4.44)%, (39.49±4.06)%, (28.70±2.76)% and (1.35±0.94), respectively.The levels of CD3+ , CD4+ , CD8+ and CD4+ /CD8+ were (54.35±4.09)%, (40.70±4.09)%, (27.62±3.60)% and (1.49±0.24) in the control group before chemotherapy, respectively.While after chemotherapy were (44.27±6.67)%, (35.39±4.96)%, (30.48±3.43)% and (1.17±0.20). After treatment, the levels of CD3+ , CD4+ , CD4+ / CD8+ decreased and CD8+ increased, but there had no significant difference(P>0.05). After treatment, CD3+ (decreased from(54.35±4.09)% to (44.27±6.67)%), CD4+ (decreased from (40.70±4.09)% to (35.39±4.96)%), CD4+ /CD8+ ((decreased from (1.49±0.24) to (1.17±0.20)), the difference was statistically significant(t value was 7.17, 4.60, 5.71, -3.02, P value was 0.000, 0.000, 0.002, 0.000). Compared with control group, the levels of CD3+ 、CD4+ 、CD4+ / CD8+ in treatment group increased and CD8+ decreased significantly (all P<0.01). \n \n \nConclusion \nGarlicin capsule can improve the depression of immune function caused by chemotherapy. \n \n \nKey words: \nBreast cancer; Garlicin capsule; Chemotherapy; Immune function","PeriodicalId":10365,"journal":{"name":"中国综合临床","volume":"35 1","pages":"337-341"},"PeriodicalIF":0.0000,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of Garlicin Capsule on Cellular Immune Function in Patients with Breast Cancer undergoing Chemotherapy\",\"authors\":\"Qi Zhou, Haiping Zhang\",\"doi\":\"10.3760/CMA.J.ISSN.1008-6315.2019.04.010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective \\nTo investigate the effects of garlicin capsule on immune function in patients with breast cancer undergoing chemotherapy. \\n \\n \\nMethods \\nForm April 2018 to October 2018, 62 patients with breast cancer were treated by operation in Tangshan People′s Hospital and pathologically diagnosed as breast cancer.Random number table method was used to divide the patients into treatment group and control group, with 31 cases in each group.The treatment group was given garlicin capsule combined with EC regimen( the first day(epirubicin hydrochloride injection 90 mg/m2 + cyclophosphamide 90 mg/m2) , 21 days for one cycle, four consecutive cycles), while the control group was given EC regimen alone for 4 courses.The occurrence of adverse reactions was recorded.T lymphocyte subsets were detected before and after treatment to evaluate the immune function of the body. \\n \\n \\nResults \\nThere was no significant difference in the number of adverse reactions between the two groups after treatment (Seventy in the treatment group and 69 in the control group) (P>0.05). The levels of CD3+ , CD4+ , CD8+ and CD4+ /CD8+ were (53.76±4.29)%, (40.19±3.71)%, (28.61±2.75)% and (1.41±0.16) in the treatment group before chemotherapy, respectively.While after chemotherapy were (52.41±4.44)%, (39.49±4.06)%, (28.70±2.76)% and (1.35±0.94), respectively.The levels of CD3+ , CD4+ , CD8+ and CD4+ /CD8+ were (54.35±4.09)%, (40.70±4.09)%, (27.62±3.60)% and (1.49±0.24) in the control group before chemotherapy, respectively.While after chemotherapy were (44.27±6.67)%, (35.39±4.96)%, (30.48±3.43)% and (1.17±0.20). After treatment, the levels of CD3+ , CD4+ , CD4+ / CD8+ decreased and CD8+ increased, but there had no significant difference(P>0.05). After treatment, CD3+ (decreased from(54.35±4.09)% to (44.27±6.67)%), CD4+ (decreased from (40.70±4.09)% to (35.39±4.96)%), CD4+ /CD8+ ((decreased from (1.49±0.24) to (1.17±0.20)), the difference was statistically significant(t value was 7.17, 4.60, 5.71, -3.02, P value was 0.000, 0.000, 0.002, 0.000). Compared with control group, the levels of CD3+ 、CD4+ 、CD4+ / CD8+ in treatment group increased and CD8+ decreased significantly (all P<0.01). \\n \\n \\nConclusion \\nGarlicin capsule can improve the depression of immune function caused by chemotherapy. \\n \\n \\nKey words: \\nBreast cancer; Garlicin capsule; Chemotherapy; Immune function\",\"PeriodicalId\":10365,\"journal\":{\"name\":\"中国综合临床\",\"volume\":\"35 1\",\"pages\":\"337-341\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国综合临床\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1008-6315.2019.04.010\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国综合临床","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1008-6315.2019.04.010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

目的探讨大蒜素胶囊对乳腺癌化疗患者免疫功能的影响。方法2018年4月至2018年10月，唐山市人民医院62例乳腺癌患者行手术治疗，病理诊断为乳腺癌。采用随机数字表法将患者分为治疗组和对照组，每组31例。治疗组给予大蒜素胶囊联合EC方案(第1天(盐酸表柔比星注射液90 mg/m2 +环磷酰胺90 mg/m2)， 21 d, 1个周期，连续4个周期)，对照组单独给予EC方案，疗程4个疗程。记录不良反应发生情况。治疗前后检测T淋巴细胞亚群，评价机体免疫功能。结果两组患者治疗后不良反应发生次数(治疗组70例，对照组69例)比较，差异无统计学意义(P < 0.05)。化疗前治疗组CD3+、CD4+、CD8+及CD4+ /CD8+水平分别为(53.76±4.29)%、(40.19±3.71)%、(28.61±2.75)%和(1.41±0.16)。化疗后分别为(52.41±4.44)%、(39.49±4.06)%、(28.70±2.76)%、(1.35±0.94)%。对照组化疗前CD3+、CD4+、CD8+及CD4+ /CD8+水平分别为(54.35±4.09)%、(40.70±4.09)%、(27.62±3.60)%和(1.49±0.24)。化疗后分别为(44.27±6.67)%、(35.39±4.96)%、(30.48±3.43)%、(1.17±0.20)%。治疗后CD3+、CD4+、CD4+ / CD8+水平降低，CD8+升高，但两组比较差异无统计学意义(P < 0.05)。治疗后CD3+(由(54.35±4.09)%降至(44.27±6.67)%)、CD4+(由(40.70±4.09)%降至(35.39±4.96)%)、CD4+ /CD8+(由(1.49±0.24)%降至(1.17±0.20))，差异均有统计学意义(t值分别为7.17、4.60、5.71、-3.02,P值分别为0.000、0.000、0.002、0.000)。与对照组相比，治疗组CD3+、CD4+、CD4+ / CD8+水平显著升高，CD8+水平显著降低(均P<0.01)。结论大蒜素胶囊可改善化疗引起的免疫功能低下。关键词:乳腺癌;外胶囊;化疗;免疫功能

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Effect of Garlicin Capsule on Cellular Immune Function in Patients with Breast Cancer undergoing Chemotherapy

Objective To investigate the effects of garlicin capsule on immune function in patients with breast cancer undergoing chemotherapy. Methods Form April 2018 to October 2018, 62 patients with breast cancer were treated by operation in Tangshan People′s Hospital and pathologically diagnosed as breast cancer.Random number table method was used to divide the patients into treatment group and control group, with 31 cases in each group.The treatment group was given garlicin capsule combined with EC regimen( the first day(epirubicin hydrochloride injection 90 mg/m2 + cyclophosphamide 90 mg/m2) , 21 days for one cycle, four consecutive cycles), while the control group was given EC regimen alone for 4 courses.The occurrence of adverse reactions was recorded.T lymphocyte subsets were detected before and after treatment to evaluate the immune function of the body. Results There was no significant difference in the number of adverse reactions between the two groups after treatment (Seventy in the treatment group and 69 in the control group) (P>0.05). The levels of CD3+ , CD4+ , CD8+ and CD4+ /CD8+ were (53.76±4.29)%, (40.19±3.71)%, (28.61±2.75)% and (1.41±0.16) in the treatment group before chemotherapy, respectively.While after chemotherapy were (52.41±4.44)%, (39.49±4.06)%, (28.70±2.76)% and (1.35±0.94), respectively.The levels of CD3+ , CD4+ , CD8+ and CD4+ /CD8+ were (54.35±4.09)%, (40.70±4.09)%, (27.62±3.60)% and (1.49±0.24) in the control group before chemotherapy, respectively.While after chemotherapy were (44.27±6.67)%, (35.39±4.96)%, (30.48±3.43)% and (1.17±0.20). After treatment, the levels of CD3+ , CD4+ , CD4+ / CD8+ decreased and CD8+ increased, but there had no significant difference(P>0.05). After treatment, CD3+ (decreased from(54.35±4.09)% to (44.27±6.67)%), CD4+ (decreased from (40.70±4.09)% to (35.39±4.96)%), CD4+ /CD8+ ((decreased from (1.49±0.24) to (1.17±0.20)), the difference was statistically significant(t value was 7.17, 4.60, 5.71, -3.02, P value was 0.000, 0.000, 0.002, 0.000). Compared with control group, the levels of CD3+ 、CD4+ 、CD4+ / CD8+ in treatment group increased and CD8+ decreased significantly (all P<0.01). Conclusion Garlicin capsule can improve the depression of immune function caused by chemotherapy. Key words: Breast cancer; Garlicin capsule; Chemotherapy; Immune function

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中国综合临床

CiteScore

0.10

自引率

0.00%

发文量

16855

期刊介绍： Clinical Medicine of China is an academic journal organized by the Chinese Medical Association (CMA), which mainly publishes original research papers, reviews and commentaries in the field. Clinical Medicine of China is a source journal of Peking University (2000 and 2004 editions), a core journal of Chinese science and technology, an academic journal of RCCSE China Core (Extended Edition), and has been published in Chemical Abstracts of the United States (CA), Abstracts Journal of Russia (AJ), Chinese Core Journals (Selection) Database, Chinese Science and Technology Materials Directory, Wanfang Database, China Academic Journal Database, JST Japan Science and Technology Agency Database (Japanese) (2018) and other databases.